Pharmaceutical or nutraceutical formulations are provided for treating inflammation in a subject in need thereof, as well as methods of treating inflammation in a subject in need thereof by administering one of the formulations. In some aspects, the pharmaceutical or nutraceutical formulation includes an effective amount of (i) palmitoylethanolamide or a derivative thereof, and (ii) one, two, three or more different small-molecule polyphenols or derivatives thereof to alleviate one or more causes or symptoms of the inflammation in the subject. In some aspects, the formulations include all three, e.g. the formulations includes (i) palmitoylethanolamide or a derivative thereof, (ii) quercetin or a derivative thereof, and (iii) curcumin or a derivative thereof. In some instances, the components (i)-(iii) discussed above are present at a mass ratio of about (i) 4 mg to 6 mg of palmitoylethanolamide or a derivative thereof to (ii) about 0.5 to 2.5 mg curcumin or a derivative thereof, and (iii) about 0.5 mg to 1.5 mg quercetin or a derivative thereof.

Pharmaceutical or nutraceutical formulations are provided for treating inflammation in a subject in need thereof, as well as methods of treating inflammation in a subject in need thereof by administering one of the formulations. In some aspects, the pharmaceutical or nutraceutical formulation includes an effective amount of (i) palmitoylethanolamide or a derivative thereof, and (ii) one, two, three or more different small-molecule polyphenols or derivatives thereof to alleviate one or more causes or symptoms of the inflammation in the subject. In some aspects, the formulations include all three, e.g. the formulations includes (i) palmitoylethanolamide or a derivative thereof, (ii) quercetin or a derivative thereof, and (iii) curcumin or a derivative thereof. In some instances, the components (i)-(iii) discussed above are present at a mass ratio of about (i) 4 mg to 6 mg of palmitoylethanolamide or a derivative thereof to (ii) about 0.5 to 2.5 mg curcumin or a derivative thereof, and (iii) about 0.5 mg to 1.5 mg quercetin or a derivative thereof.

Described herein are compositions comprising capsaicin and methods of treating muscle cramping in a subject, comprising orally administering to the subject a composition comprising capsaicin and an excipient.

A composition for use in a method for the treatment of an amino acid deficiency to a non-mammalian monogastric animal, such as a poultry animal, a fish or a crustacean is described, wherein said composition comprises (i) a mixture of active components comprising or, alternatively, consisting of at least one amino acid or an analogue, (ii) a lipid matrix embedding said (i) mixture of active components and, optionally, (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient. Furthermore, a feed or feed additive for a non-mammalian monogastric animal, such as poultry species and/or aquatic species comprising the composition is also described.

A composition for use in a method for the treatment of an amino acid deficiency to a non-mammalian monogastric animal, such as a poultry animal, a fish or a crustacean is described, wherein said composition comprises (i) a mixture of active components comprising or, alternatively, consisting of at least one amino acid or an analogue, (ii) a lipid matrix embedding said (i) mixture of active components and, optionally, (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient. Furthermore, a feed or feed additive for a non-mammalian monogastric animal, such as poultry species and/or aquatic species comprising the composition is also described.

The present disclosure relates to a conjugated prodrug comprising a peptide conjugated to an antibiotic molecules via a cleavable linker and pharmaceutical compositions thereof. Also disclosed are methods of enhancing the intracellular concentration of an antibiotic agent in a bacterium and methods of treating a patient for a bacterial infection.

Compositions used and methods are disclosed for regulation of homeostasis of host cortisol and improving sleep quality including a composition derived from enriched for one or more phenylpropanoid acids and benzoxazinoids or extracts that are enriched for one or more phenylpropanoid acids and benzoxazinoids. Compositions of enriched for one or more phenylpropanoid acids and benzoxazinoids maintain homeostasis of host stress hormone, cortisol, selectively binds to MT2 over MT1 receptor, improves sleep quality by enhancing the deep sleep stage of sleep, increases total sleep time and deep sleep time, improves overall mental well-being measured by the Pittsburgh Sleep Quality Index (PSQI) and Profile of Mood States (POMS), provides positive mood support and enhances emotional well-being; maintains homeostasis of biomarkers—serotonin, melatonin, GABA in formulation in a mammal disclosed that includes administering an effective amount of a composition from 0.01 mg/kg to 1000 mg/kg body weight of the mammal.

Compositions used and methods are disclosed for regulation of homeostasis of host cortisol and improving sleep quality including a composition derived from enriched for one or more phenylpropanoid acids and benzoxazinoids or extracts that are enriched for one or more phenylpropanoid acids and benzoxazinoids. Compositions of enriched for one or more phenylpropanoid acids and benzoxazinoids maintain homeostasis of host stress hormone, cortisol, selectively binds to MT2 over MT1 receptor, improves sleep quality by enhancing the deep sleep stage of sleep, increases total sleep time and deep sleep time, improves overall mental well-being measured by the Pittsburgh Sleep Quality Index (PSQI) and Profile of Mood States (POMS), provides positive mood support and enhances emotional well-being; maintains homeostasis of biomarkers—serotonin, melatonin, GABA in formulation in a mammal disclosed that includes administering an effective amount of a composition from 0.01 mg/kg to 1000 mg/kg body weight of the mammal.

Compositions and methods are provided for decreasing processing of chondroitin sulfate proteoglycan 4 (CSPG) in treatment of gliomas, which treatment may be combined with administration of an immune-oncology agent.

Compositions and methods are provided for decreasing processing of chondroitin sulfate proteoglycan 4 (CSPG) in treatment of gliomas, which treatment may be combined with administration of an immune-oncology agent.